Proposals to streamline regulatory approval of new drugs would bode well for biotech companies like Amgen in Thousand Oaks. Thousand Oaks-based Amgen reported revenue of $6 billion in the fourth quarter of 2016, besting analyst estimates of $5.74 billion and increasing more than 7 percent from the fourth quarter of 2015. The world’s largest biotech…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
